Global Sanger Sequencing Service Market is valued USD 75.32 Billion in 2019 and is projected is to exhibit 0.5% CAGR during the forecast period. The market is projected to be around USD 78 Billion by 2026. The market is driven by the growing demand for pharmacogenomics in drug discovery & development.

Award-winning sanger sequencing services produce high-quality results, industry-leading customer service, and fast turnaround times at competitive prices. GENEWIZ is the partner of choice for academic, GLP, pharmaceutical, biotechnology, and government institutions around the world.
Sanger Sequencing Service Market Dynamics
The factors that drive the growth of the Sanger sequencing service market are such as the growing demand for pharmacogenomics in drug discovery & development, technological development, decreasing prices of sequencing, growing demand for affordable genotyping services, rising incidence, and awareness on genetic diseases and personalized medicine, and high use of genetic analysis in animals and plants. Furthermore, the advantages associated with Sanger’s sequencing, and the advance in genome mapping programs boost the growth of the Sanger’s sequencing services market.

Additionally, the rise in investment in R&D and an increase in sequencing end-users have supplemented the market growth. At the same time, the lack of skilled professionals and standardization concerns associated with sequencing procedures hamper the growth of the industry. The untapped potential of developing markets and the use of cloud computing as a potential data management service are supposed to provide profitable opportunities for market expansion.
Sanger Sequencing Service Market Insight
North America is estimated to account for the largest market share of the Sanger sequencing service market in 2017, followed by the Asia Pacific. China is projected to witness significant growth in the next few years, due to an increase in R&D investment and a surge in end-users of Sanger’s sequencing. Furthermore, the Chinese region presents remarkable opportunities for venture capitalists and investors, as the developed markets are comparatively saturated. Rise in collaborations, partnerships, and agreements among market players, the surge in government funding for translational research, improving healthcare infrastructure are expected to increase demand for Sanger sequencing services in the Asia Pacific region. An increase in competition in mature markets and relatively less-stringent regulations and data requirements as compared to developed nations are other key factors that make the Asia Pacific an attractive region for stakeholders.
Sanger Sequencing Service Market Segmentation
The global Sanger Sequencing Service Market is segmented into application, end-user, and region. On the basis of the application the market is divided into diagnostics, biomarkers & cancer, reproductive health, personalized medicine, forensics, others. Based on end-user the market is segmented into academic & government research institutes, pharmaceutical companies, biotechnology companies, hospitals & clinics. And based on the geography the market is further segregated into North America, Latin America, Europe and Asia Pacific.
Sanger Sequencing Service Market Competitive Landscape
The key players in Sanger Sequencing Service Market are listed as BioScience, GenScript Biotech Corporation, Thermo Fisher Scientific, Inc., LGC Science Group Limited, Fasteris SA, CeMIA SA, Quintara Biosciences, GenHunter Corporation, GENEWIZ, SciGenom Labs Pvt. Limited, and Microsynth AG. Inc., Nucleics, and Other.